Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 9/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4195675 | 0.80 | NAAA (0.40) | FAAHMGLLLMNAMAPK1RAB9A | |
| SCHEMBL1074852 | 0.76 | LMNA (0.49) | FAAHMGLLPOLBERN1LMNA | |
| SCHEMBL4185530 | 0.75 | FAAH (0.39) | FAAHMGLLERN1LMNAMAPK1 | |
| SCHEMBL21641600 | 0.74 | POLB (0.38) | POLBGAASMN1; SMN2LMNA | |
| SCHEMBL8665411 | 0.74 | TSHR (0.59) | POLBSMN1; SMN2LMNAMAPK1RAB9A | |
| SCHEMBL22647326 | 0.72 | ERN1 (0.33) | FAAHMGLLERN1NPSR1CYP3A4 | |
| SCHEMBL30900664 | 0.71 | FAAH (0.31) | FAAHMGLLERN1NPSR1 | |
| SCHEMBL625322 | 0.70 | SMN1; SMN2 (0.53) | POLBGAASMN1; SMN2RAB9A | |
| SCHEMBL4194016 | 0.70 | GAA (0.40) | FAAHMGLLPOLBGAALMNA | |
| SCHEMBL21074365 | 0.70 | ERN1 (0.32) | FAAHMGLLERN1NPSR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110105372-B | Preparation method of R-7- (benzyloxy) -tetrahydro-1H-oxazine pyrido-triazine-6, 8-diketone | 南京焕然生物科技有限公司 | 2022-05-10 | — | — | CN | claimed |
| CN-110105372-A | A kind of R-7- (benzyloxy)-tetrahydro -1H- oxazines and pyrido-triazine -6,8- diketone preparation method | 南京焕然生物科技有限公司 | 2019-08-09 | — | — | CN | claimed |
| US-20230287004-A1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF | SHIONOGI & CO., LTD. (JP) | 2023-09-14 | — | — | US | disclosed |
| CN-110105372-B | Preparation method of R-7- (benzyloxy) -tetrahydro-1H-oxazine pyrido-triazine-6, 8-diketone | 南京焕然生物科技有限公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-110105372-B | Preparation method of R-7- (benzyloxy) -tetrahydro-1H-oxazine pyrido-triazine-6, 8-diketone | 南京焕然生物科技有限公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-109721615-B | Inhibitors of influenza virus replication and uses thereof | 广东东阳光药业有限公司 | 2020-12-29 | — | — | CN | disclosed |
| US-20200283454-A1 | INFLUENZA VIRUS REPLICATION INHIBITOR AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2020-09-10 | — | — | US | disclosed |
| EP-3686201-A1 | INFLUENZA VIRUS REPLICATION INHIBITOR AND USE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2020-07-29 | — | — | EP | disclosed |
| CN-110105372-A | A kind of R-7- (benzyloxy)-tetrahydro -1H- oxazines and pyrido-triazine -6,8- diketone preparation method | 南京焕然生物科技有限公司 | 2019-08-09 | — | — | CN | disclosed |
| CN-110105372-A | A kind of R-7- (benzyloxy)-tetrahydro -1H- oxazines and pyrido-triazine -6,8- diketone preparation method | 南京焕然生物科技有限公司 | 2019-08-09 | — | — | CN | disclosed |
| US-20180118760-A1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF | SHIONOGI & CO., LTD. (JP) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287004-A1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF | C3AR1, NR4A1, HAVCR2 | FAAH 4646/4885MGLL 4779/4885POLB 439/4885 |
| US-20200283454-A1 | INFLUENZA VIRUS REPLICATION INHIBITOR AND USE THEREOF | RTF2, POLRMT, RTF1 | FAAH 1091/4885MGLL 934/4885POLB 11/4885 |
| US-20180118760-A1 | SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF | C3AR1, NR4A1, HAVCR2 | FAAH 4646/4885MGLL 4779/4885POLB 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.